Yevgeniya Le1, Sylvain Fraineau2, Priya Chandran2, Mitchell Sabloff3, Marjorie Brand2,3, Jessie R Lavoie4, Rémi Gagne4,5, Michael Rosu-Myles4, Carole L Yauk4,5, Richard B Richardson6,7, David S Allan8,9. 1. Canadian Nuclear Laboratories, Chalk River, ON, K0J 1 J0, Canada. 2. Regenerative Medicine Program, Ottawa Hospital Research Institute, 501 Smyth Rd., Box 704, Ottawa, ON, K1H 8L6, Canada. 3. Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 4. Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada. 5. Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, ON, Canada. 6. Canadian Nuclear Laboratories, Chalk River, ON, K0J 1 J0, Canada. richard.richardson@cnl.ca. 7. McGill Medical Physics Unit, Montreal General Hospital, Montreal, QC, Canada. richard.richardson@cnl.ca. 8. Regenerative Medicine Program, Ottawa Hospital Research Institute, 501 Smyth Rd., Box 704, Ottawa, ON, K1H 8L6, Canada. daallan@ohri.ca. 9. Department of Medicine, University of Ottawa, Ottawa, ON, Canada. daallan@ohri.ca.
Abstract
PURPOSE: The role of bone marrow-derived mesenchymal stem/stromal cells (MSCs) in creating a permissive microenvironment that supports the emergence and progression of acute myeloid leukemia (AML) is not well established. We investigated the extent to which adipogenic differentiation in normal MSCs alters hematopoietic supportive capacity and we undertook an in-depth comparative study of human bone marrow MSCs derived from newly diagnosed AML patients and healthy donors, including an assessment of adipogenic differentiation capacity. FINDINGS: MSCs from healthy controls with partial induction of adipogenic differentiation, in comparison to MSCs undergoing partial osteogenic differentiation, expressed increased levels of hematopoietic factors and induced greater proliferation, decreased quiescence and reduced in vitro hematopoietic colony forming capacity of CD34(+) hematopoietic stem and progenitor cells (HSPCs). Moreover, we observed that AML-derived MSCs had markedly increased adipogenic potential and delayed osteogenic differentiation, while maintaining normal morphology and viability. AML-derived MSCs, however, possessed reduced proliferative capacity and decreased frequency of subendothelial quiescent MSCs compared to controls. CONCLUSION: Our results support the notion of a bone marrow microenvironment characterized by increased propensity toward adipogenesis in AML, which may negatively impact normal hematopoiesis. Larger confirmatory studies are needed to understand the impact of various clinical factors. Novel leukemia treatments aimed at normalizing bone marrow niches may enhance the competitive advantage of normal hematopoietic progenitors over leukemia cells.
PURPOSE: The role of bone marrow-derived mesenchymal stem/stromal cells (MSCs) in creating a permissive microenvironment that supports the emergence and progression of acute myeloid leukemia (AML) is not well established. We investigated the extent to which adipogenic differentiation in normal MSCs alters hematopoietic supportive capacity and we undertook an in-depth comparative study of human bone marrow MSCs derived from newly diagnosed AMLpatients and healthy donors, including an assessment of adipogenic differentiation capacity. FINDINGS: MSCs from healthy controls with partial induction of adipogenic differentiation, in comparison to MSCs undergoing partial osteogenic differentiation, expressed increased levels of hematopoietic factors and induced greater proliferation, decreased quiescence and reduced in vitro hematopoietic colony forming capacity of CD34(+) hematopoietic stem and progenitor cells (HSPCs). Moreover, we observed that AML-derived MSCs had markedly increased adipogenic potential and delayed osteogenic differentiation, while maintaining normal morphology and viability. AML-derived MSCs, however, possessed reduced proliferative capacity and decreased frequency of subendothelial quiescent MSCs compared to controls. CONCLUSION: Our results support the notion of a bone marrow microenvironment characterized by increased propensity toward adipogenesis in AML, which may negatively impact normal hematopoiesis. Larger confirmatory studies are needed to understand the impact of various clinical factors. Novel leukemia treatments aimed at normalizing bone marrow niches may enhance the competitive advantage of normal hematopoietic progenitors over leukemia cells.
Authors: V Lokesh Battula; Ye Chen; Maria da Graca Cabreira; Vivian Ruvolo; Zhiqiang Wang; Wencai Ma; Sergej Konoplev; Elizabeth Shpall; Karen Lyons; Dirk Strunk; Carlos Bueso-Ramos; Richard Eric Davis; Marina Konopleva; Michael Andreeff Journal: Blood Date: 2013-06-05 Impact factor: 22.113
Authors: Priya Chandran; Yevgeniya Le; Yuhua Li; Mitchell Sabloff; Jelica Mehic; Michael Rosu-Myles; David S Allan Journal: Leuk Res Date: 2015-02-02 Impact factor: 3.156
Authors: Rafael Diaz de la Guardia; Belen Lopez-Millan; Jessie R Lavoie; Clara Bueno; Julio Castaño; Maite Gómez-Casares; Susana Vives; Laura Palomo; Manel Juan; Julio Delgado; Maria L Blanco; Josep Nomdedeu; Alberto Chaparro; Jose Luis Fuster; Eduardo Anguita; Michael Rosu-Myles; Pablo Menéndez Journal: Stem Cell Reports Date: 2017-05-18 Impact factor: 7.765
Authors: Thomas H Ambrosi; Antonio Scialdone; Antonia Graja; Sabrina Gohlke; Anne-Marie Jank; Carla Bocian; Lena Woelk; Hua Fan; Darren W Logan; Annette Schürmann; Luis R Saraiva; Tim J Schulz Journal: Cell Stem Cell Date: 2017-03-16 Impact factor: 24.633
Authors: Juliana Barrera-Ramirez; Jessie R Lavoie; Harinad B Maganti; William L Stanford; Caryn Ito; Mitchell Sabloff; Marjorie Brand; Michael Rosu-Myles; Yevgeniya Le; David S Allan Journal: Stem Cell Rev Rep Date: 2017-12 Impact factor: 5.739